AUG 18, 2026 · JOURNAL ARTICLE
Real-world efficacy and safety profile of low-dose cadonilimab in recurrent or metastatic cervical cancer as first-line therapy
Frontiers in Immunology
A real-world retrospective study of adequate size showing encouraging efficacy (ORR 55.6%, 12-month OS 92.1%) with manageable toxicity in R/M cervical cancer, but lacking a control arm and requiring prospective validation.
Reported
Sample size (efficacy-evaluable)133
Primary endpoint: Objective Respo…55.6%
Disease Control Rate83.5%